80
Participants
Start Date
January 17, 2012
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)
Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
Department of Nephrology , Tenon hospital - APHP, Paris
Assistance Publique - Hôpitaux de Paris
OTHER